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Abstract: Aim: To evaluate the prognostic value of circulating osteonectin for cumulative survival and hospitalization in 
patients with ischemic chronic heart failure (CHF). 
Methods: One hundred fifty four patients with ischemic symptomatic moderate-to-severe CHF were prospectively 
enrolled at discharge from the hospital. Observation period was up to 3 years (156 weeks). Blood samples for 
hematology, chemistry, and biomarker measurements were collected at baseline prior to study entry. ELISA method for 
measurement of circulating osteonectin (OSN) was used.  
Results: During a median follow-up of 2.18 years we identified 21 deaths and 106 readmissions. Medians of circulating 
levels of OSN in survivors patient and subjects who died were 670.96 ng/mL (95% confidence interval [CI] = 636.53-
705.35 ng/mL) and 907.84 ng/mL (95% CI = 878.02-937.60 ng/mL). Receive Operation Characteristic curve analysis has 
shown the best balanced cutoff point of OSN concentration for cumulative survival equal 845.15 ng/mL. A significantly 
divergence of Kaplan-Meier survival curves constructed for patients with high (> 845.15 ng/mL) and low (<845.15 ng/mL) 
concentrations of OSN was found. Circulating OSN independently predicted all-cause mortality (OR = 1.23; 95% CI = 
1.10–1.36; P < 0.001), CHF-related death (OR = 1.46; 95% CI 1.22–1.80; P < 0.001), and also CHF-related readmission 
(OR = 1.92; 95% CI = 1.77 – 2.45; P<0.001) within 3 year of follow-up period. 
Conclusion: Increased circulating SPARC family member OSN associates with increased 3-year CHF-related death, all-
cause mortality, and risk for readmission due to CHF. 
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1. INTRODUCTION 
Matrix cellular proteins, such as secreted protein 
acidic and rich in cysteine (SPARC), play a key role in 
post-synthetic procollagen processing in myocardium 
and regulate cell adhesion, growth factor activity and 
cell cycle in heart failure [1]. It has found SPARC family 
member osteonectin (OSN) causes myocardial 
hypertrophy, increased fibrillar collagen content, 
stimulates cell signaling, adhesion, survival, 
proliferation, and migration in several cell types, as well 
as mediates calcification of the vascular wall, 
coagulation, and endothelial dysfunction [2]. Moreover, 
OSN induces increased collagen deposition in 
response to acute myocardial infarction (MI) and as 
result cardiac hypertrophy and impaired cardiac 
function [3]. Recent animal studies have revealed that 
increased circulating OSN closely associates with 
higher incidence of mortality following MI [4, 5]. 
Therefore, increased rates of rupture and newly chronic 
heart failure (CHF) over the first 14 days after MI may 
relate to elevated OSN [4, 5]. However, the causative  
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role of OSN in the CHF has not defined. The objective 
of this study was to evaluate the prognostic value of 
circulating OSN for survival and readmission in patients 
with ischemic CHF. 
2. METHODS 
The study prospectively evolved 154 patients (86 
male, 68 females) aged 48 to 62 years with ischemic 
symptomatic CHF with II-IV NYHA (New York Heart 
Association) class. Chronic heart failure (CHF) was 
diagnosed according to current European Society of 
Cardiology clinical guidelines [6]. All the patients have 
given their written informed consent for participation in 
the study. The following are exclusion criteria: Q-wave 
and non-Q-wave MI within 3 months before study entry; 
severe kidney and liver diseases that may affect clinical 
outcomes; malignancy; creatinin plasma level above 
440 μmol/L; estimated GFR < 35 ml/min/2; brain injury 
within 3 months before the enrollment; body mass 
index above 30 kg/m
2
; pulmonary edema; 
tachyarrhythmia; valvular heart disease; thyrotoxicosis; 
ischemic stroke; intracranial hemorrhage; acute 
infections; surgery; trauma; all the ischemic events 
within 3 previous months; inflammations within a 
previous month; neoplasm; pregnancy; implanted 
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pacemaker, any disorder that may discontinue patient’s 
participation in the study according to investigators; 
and patient’s refusal to participate in the study or to 
give his consent for it. Follow-up period was up to 3 
years (156 weeks). We also analyzed cumulative 
survival related to CHF, and therefore all-cause 
mortality was examined additionally. 
2.1. Methods for Visualization of Coronary Arteries 
Multispiral computed tomography angiography 
and/or angiographic study have been performed to 
verify the ischemic nature of CHF. Angiographic 
procedure was used when ischemic sings were 
presented at baseline and no myocardial infarction was 
found previously. Multispiral computed tomography 
angiography was performed when no ischemic sings / 
previously documented old myocardial infarction at 
baseline were detected, but signs and symptoms of 
CHF were presented. Multispiral computed tomography 
angiography has performed for all the patients prior to 
the study entry. The coronary artery wall structure was 
investigated by contrast-enhanced spiral computed 
tomography angiography [7] on Somatom Volum Zoom 
scanner (Siemens, Erlangen, Germany) with two 
detector rows. After preliminary native scanning, non-
ionic contrast “Omnipaque” (Amersham Health, Ireland) 
was administered for the optimal image of the coronary 
arteries. To reconstruct the image, 0.6-mm-width axial 
tomographic slices were used. All patients with exiting 
atherosclerotic lesions of the coronary arteries were 
subjected to conventional angiographic examination. 
Coronary artery disease (CAD) was considered to be 
diagnosed upon availability of previous angiographic 
examinations carried out not later than 6 months ago 
provided no new cardiovascular events occurred for 
this period, and the procedure are available for assay. 
2.2. Assessment of Hemodynamics 
Transthoracic ultrasonic echocardiography was 
performed according to a conventional procedure on 
scanner equipped ACUSON (SIEMENS, Germany) in 
two-dimensional mode and Tissue Doppler Imaging 
echocardiography regimen from parasternal, subcostal, 
and apical positions over the short and long axis with 
probe  of 2.5-5 Hz. Left ventricular end-diastolic and 
end-systolic volumes were measured by modified 
Simpson’s method. Left ventricular ejection fraction 
(LVEF) was assessed in compliance with the 
requirements of American Society of Echocardiography 
[8]. Tissue Doppler echocardiography was performed in 
4-, 3- and 2-chamber views in each of 16 segments of 
the left ventricle and in 4 spots of the mitral annulus: at 
the base of posterior septal, lateral, inferior, and 
anterior left ventricular walls [9]. Peak systolic (Sm), 
early diastolic (Em), and late diastolic (m) myocardial 
velocities were measured in the mitral annulus area. 
2.3. Calculation of Glomerular Filtration Rate 
Glomerular filtration rate (GFR) was calculated 
using CKD-EPI formula [10]. 
2.4. Measurement of Biomarkers 
Blood samples were collected at baseline in the 
morning (at 7-8 a.m.) into cooled silicone test tubes, 
when patients were discharged from the hospital with 
stable clinical status. Samples were processed 
according to the recommendations of the manufacturer 
of the analytical technique used. They were centrifuged 
upon permanent cooling at 6,000 rpm for 3 minutes. 
Then plasma samples were stored at a temperature -
70
0
C. Circulating OSN level was determined by ELISA 
method (Bender MedSystems GmbH, Vienna, Austria). 
N-terminal pro-brain natriuretic peptide (NT-pro-BNP) 
concentration was measured by immunoelectro- 
chemoluminescent assay using kit produced by R&D 
Systems (USA) on Elecsys 1010 analyzer (Roche, 
Mannheim, Germany). Concentrations of total 
cholesterol (TC) and cholesterol of high-density 
lipoproteins (HDL) were measured by direct 
fermentation method. 
2.5. Ethical Principles 
The investigators followed strictly all the 
requirements to clinical trials in conformity with the 
World Medical Association (WMA) Declaration of 
Helsinki, 1964, Good Clinical Practice provided by 
International Conference on Harmonization (GCP-ICH), 
Council of Europe Convention for the Protection of. 
Human Rights and Dignity of the Human Being in view 
of using achievements in biology and medicine, 
Convention on Human Rights and Biomedicine, 
including Additional Protocol to the Convention on 
Human Rights and Biomedicine, concerning 
Biomedical Research, and legislation of Ukraine.  
2.6. Statistical Analysis 
Statistical analysis of the results obtained was 
performed in SPSS system for Windows, Version 20 
(SPSS Inc, Chicago, IL, USA). The data were 
presented as mean () and standard error (±SE) or 
95% confidence interval (CI); median () and 
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interquartile range (IQR). A design of the study (non-
randomized prospective open cohort study) with two-
tailed hypothesis requires the alpha level 0.05 and 
beta-level 0.20. The sample size was computed on 
http://www.sealedenvelope.com/power/binary-
superiority/ taken into consideration that the level of 
significance is 5%, Z/2 is 1.96. The result shows that 
the total sample size required is 139 patients. 
Adjustment for non-compliance/cross-over and lost for 
follow-up patients (10%) the total sample size was 
calculated 154 subjects. The hypothesis of normal 
distribution of the parameters analyzed was checked 
by means of Shapiro–Wilk test and Kolmogorov-
Smirnov test. To compare the main parameters of 
patients’ groups (subject to the type of distribution of 
the parameters analyzed), two-tailed Student t-test or 
Shapiro–Wilk U-test were used. To compare 
categorical variables between groups, Chi2 test (2) 
and Fisher F exact test were used. The circulating OSN 
and NT-pro-BNP level in the blood failed to have a 
normal distribution, while distribution of the total 
cholesterol and cholesterol fractions had a normal 
character (estimated by means of Kolmogorov-Smirnov 
test) and was not subjected to any mathematical 
transformation. Receive Operation Characteristic 
(ROC) analysis was carried out to identify the optimal 
cutoff points of the OSN concentration with predicted 
value. The difference between the areas under ROC 
curves was calculated with the method of DeLong al. 
(1988) [11] and reclassification measures (index 
discrimination improvement - IDI) [12]. Odds ratio (OR) 
and 95% confidence interval (95% CI) were calculated 
for all the independent predictors of survival of the 
patients. A calculated difference of P<0.05 was 
considered significant. 
3 RESULTS  
3.1. General Characteristics of Study Patient 
Population 
A median follow-up was 2.18 years. We identified 
21 died cases included 18 CHF-related deaths. 
Additionally, 106 subjects were readmitted in the 
hospital due to advance CHF (17 cases in died cohort 
and 89 cases in survivors cohort). Table 1 shows a 
general characteristic of the patients included in the 
study. As one can see from Table 1, no substantial age 
and gender differences were found among persons 
who died and survived. No any differences were 
determined between both cohorts in body mass index 
(BMI), glomerular filtration rate (GFR), HbA1c, fasting 
blood glucose level, blood creatinine level, total 
cholesterol (TC), low-density lipoprotein cholesterol 
(LDL-C) and high-density lipoprotein cholesterol (HDL-
C), numerous of coronary vessels damaged. Therefore, 
no difference was found between both cohorts in 
systemic office blood pressure (BP) and heart rate 
(HR). Incidences of type 2 diabetes mellitus among 
patients enrolled in both cohorts was 38.1% and 33.8% 
(P=0.06). Noted that there was not a statistically 
significant change in /m and /Em between both 
cohorts, while decreased left ventricular ejection 
fraction value was detected in died patients. At the 
same time, the level of circulating NT-pro-BNP was 
statistically significantly higher in died patients than in 
survivor’s persons. When analyzing details of 
pharmacotherapy, no substantial differences were 
found between two cohorts with regard to 
administration of the majority of drugs 
3.2. Circulating OSN Level in Survived and Died 
Patients 
Means of circulating level of OSN in survivors and 
died patients were 670.96 ng/mL (95% confidence 
interval [CI] = 636.53-705.35 ng/mL) and 907.84 ng/mL 
(95% CI = 878.02-937.60 ng/mL) (P<0.001). 
3.3. The Predictive Value of OSN Concentration in 
Study Patient Population 
Multivariate logistic regression was used to assess 
whether any combination of assays was able to better 
discriminate between survivors and died patients. In 
the logistic regression analysis, the main factors 
independently related with cumulative mortality and 
CHF-related readmissions were some biomarkers 
(OSN alone, NT-pro-BNP alone), LVEF, T2DM, and 
three- and multi-vessel lesion. Circulating OSN 
independently predicted all-cause mortality (OR = 1.23; 
95% CI = 1.10–1.36; P < 0.001), CHF-related death 
(OR = 1.46; 95% CI 1.22–1.80; P < 0.001), and also 
CHF-related readmissions (OR = 1.92; 95% CI = 1.77 – 
2.45; P<0.001) up to 3 years (Table 2). NT-pro-BNP 
and LVEF remained statistically significant for all 
categories: all-cause mortality, CHF-related death, and 
CHF-related readmissions, whereas T2DM and three- 
and multi-vessel lesions for all variables did not. 
Using a stepwise model selection method for 
multivariable prediction model we have investigated the 
summary effect of any combinations of OSN, NT-pro-
BNP, LVEF on all-cause mortality, CHF-related death, 
and CHF-related readmissions. We found that OSN 
alone (Model 1) and combination of OSN with NT-pro-
BNP (Model 2) remained statistically significant 
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Table 1: General characteristic of patients participating in the study 
Variables All Patients (n=154) Subjects Who Died (n=21) 
Subjects Who Survived 
(n=133) 
Age, years 58.50±6.10 57.20±6.70 59.50±7.30 
Males, n (%) 79 (51.3%) 12 (57.1%) 67 (50.3%) 
Arterial hypertension, n (%) 73 (47.4%) 12 (57.1%) 61 (45.9%) 
Hyperlipidemia, n (%) 61 (39.6%) 9 (42.8%) 52 (39.1%) 
T2DM, n (%) 53 (34.4%) 8 (38.1%) 45 (33.8%) 
Adherence to smoking, n (%) 31 (20.1%) 7 (33.3%) 24 (29.3%) 
II Class NYHA 41 (26.6%) 6 (28.6%) 35 (26.3%) 
III Class NYHA 74 (48.1%) 9 (42.8%) 65 (48.9%) 
IV Class NYHA 39 (25.3%) 6 (28.6%) 33 (24.8%) 
BMI, kg/m
2
 23.9 (95% CI=22.8–26.1) 23.7 (95% CI=22.5–27.3) 24.2 (95% CI=22.0–27.9) 
GFR, mL/min/1.73 m
2
 83.4 (95% CI=70.2–91.3) 82.1 (95% CI=69.9–93.1) 85.2 (95% CI=70.3–112.5) 
HbA1c, % 6.5(95% CI=4.7-8.6) 6.3 (95% CI=4.4-9.0) 7.0 (95% CI=4.3-9.2) 
Fasting blood glucose, mmol/L 4.95 (95% CI=3.8-8.0) 4.80 (95% CI=3.6-8.5) 5.40 (95% CI=3.4-9.1) 
Creatinine, μmol/L 72.6 (95% CI=61.3–82.5) 70.5 (95% CI=59.6–88.3) 74.9 (95% CI=65.1–90.3) 
Total cholesterol, mmol/L 5.1 (95% CI=4.7-5.6) 5.3 (95% CI=4.6-6.0) 5.0 (95% CI=4.2-5.8) 
LDL-C, mmol/L 3.35 (95% CI =3.16–4.02) 3.60 (95% CI =3.20–4.18) 3.02 (95% CI=2.80–3.90) 
HDL-C, mmol/L 0.92 (95% CI = 0.90–1.02) 0.94 (95% CI = 0.92–1.06) 0.88 (95% CI = 0.82–0.97) 
NT-pro-BNP, pg /mL 1266.1 (95% CI 811.5 – 2220.7) 1533.6 (95% CI 644.5 – 2560.6) 1031.2 (95% CI 704.8 – 1560.7)* 
Osteonectin, ng/mL 
788.54 (95% CI = 665.12-
912.30) 
907.84 (95% CI = 878.02-937.60) 670.96 (95% = 636.53-705.35)* 
Systolic BP, mm Hg 131±6 129±4 135±5 
Diastolic BP, mm Hg 77±4 77±5 78±5 
Heart rate, beats per 1 min. 71±5 76±6 68±3 
LVEF, % 47.60±0.82 42.80±0.76 55.40±0,80* 
/m, U 16.6±0.72 16.6±0.94 16.5±1.20 
/Em, U 16.6±0.90 16.6±1.00 16.6±0.84 
One-vessel lesion of CA, n (%) 29 (18.8%) 5 (23.8%) 24 (18.0%) 
Two-vessel lesion of CA, n (%) 64 (41.6%) 8 (38.1%) 54 (40.6%) 
Three- and multi-vessel lesion of CA, 
n (%) 
63 (40.9%) 
8 (38.1%) 55 (41.4%) 
ACEI / ARAs, n (%) 154 (100%) 21 (100%) 133 (100%) 
Acetylsalicylic acid, n (%) 130 (84.4%) 19 (90.5%) 121 (91.0%) 
Other antiaggregants, n (%) 14 (9.1%) 2 (9.5%) 12 (9.0%) 
Statins, n (%) 94 (61.0%) 14 (66.7%) 80 (60.2%) 
Metformin, n (%) 53 (34.4%) 8 (38.1%) 45 (33.8%) 
Diuretics, n (%) 139 (90.3%) 18 (85.7%) 121 (91.0%) 
Mineralcorticoid receptor antagonist 
eplerenon, n(%) 
79 (51.3%) 
9 (42.9%) 70 (52.6%) 
Note: * - statistically differences between parameters in the two groups (P<0.05); CI – confidence interval; CAD – coronary artery disease, T2DM – type two diabetes 
mellitus, GFR - Glomerular filtration rate, HDL-C - high-density lipoprotein cholesterol, LDL-C - Low-density lipoprotein cholesterol, CA - coronary arteries, BP – blood 
pressure, BMI - Body mass index, NYHA - New York Heart Association, BNP – brain natriuretic peptide, LVEF - Left ventricular ejection fraction, U – unit, Em - early 
diastolic myocardial velocity, m - late diastolic myocardial velocity, E – peak velocity of early diastolic left ventricular filling, ACEI – angiotensin-converting enzyme 
inhibitor, ARAs – angiotensin-2 receptors antagonists 
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predictors for all-cause mortality (B-coefficient=1.14, p= 
0.001, and B-coefficient=1,14, p=0.001 respectively), 
CHF-related death (B-coefficient=2.24, p= 0.003, and 
B-coefficient=2,76, p=0.008 respectively), and CHF-
related readmissions (B-coefficient=2.06, p=0.003, and 
B-coefficient=2,11, p=0.004 respectively), whereas 
combination of OSN with both NT-pro-BNP and LVEF 
(Model 4) did not (B-coefficient= 0.014, p= 0.543, and 
B-coefficient=0,016, p=0.528, and B-coefficient=0,012, 
p=0.448 respectively). NT-pro-BNP alone (Model 3) 
predicted CHF-related readmissions (B-
coefficient=1.88, p= 0.001) only, whereas all-cause 
mortality (B-coefficient=0,025, p=0.68) and CHF-
related death (B-coefficient=0,036, p=0.62) did not. In 
fact, a stepwise model selection method demonstrated 
that LVEF, T2DM and three- and multi-vessel lesions of 
coronary arteries added to combination of OSN and 
NT-pro-BNP do not offer any additional information to 
discriminate between survivors and died patients with 
CHF (B-coefficient of 0.012, 0.067, and 0.023 
respectively; p-values of 0.277, 0.300 and 0.522 
respectively). 
The optimal balanced cut-off point for OSN is 
determined by the relative importance of the sensitivity 
and specificity. ROC (Receive Operation 
Characteristic) curve analysis has shown that the best 
balanced cut-off point of OSN concentration reflected 
superiority in cumulative survival was 845.15 ng/mL 
(Figure 1). Area under ROC Curve was 0.918 (Std. 
error = 0.022; 95% CI = 0.876-0.961), sensitivity and 
specificity were 79.2% and 84.4% respectively. Derived 
from ROC curve, a NT-pro-BNP cut-off of 1250.4 pg 
/mL showed the best balanced sensitivity and 
specificity for predicting mortality and hospital 
readmission (72.3% sensitivity and 81.6% specificity). 
Using cut-off points for OSN and NT-pro-BNP over 
mentioned above we found that the discriminative 
ability for both biomarkers showed a small trend to 
increase only. Combination of both biomarkers leads 
increased sensitivity up 88.6% and specificity up 
92.4%. Discrimination Model was excellent for OSN 
alone, NT-pro-BNP alone, and their combination. For 
determination of difference between the ROC curves 
we used DeLong method and reclassification method 
(index discrimination improvement - IDI). Using DeLong 
method we found a statistical difference between areas 
under curves, that are suitable for OSN alone, NT-pro-
BNP alone and its combination (P<0.001 for all cases). 
IDI after the inclusion of NT-pro-BNP into the model 
was calculated. However, we found that adding of NT-
pro-BNP to standard model constructed on OSN does 
not improve its discrimination value (AUC 0.61 vs. 
0.918, p=0.22; and IDI=0.035, p=0.42). There was 
significantly difference between discriminates 
calculated for OSN alone and NT-pro-BNP alone (IDI = 
0.04; P<0.01). Therefore we found a significantly 
divergence of Kaplan-Meier survival curves constructed 
for patients with high (> 845.15 ng/mL) and low 
(<845.15 ng/mL) concentrations of OSN (Figure 2). 
The curve’s divergence affected accumulation of 
clinical events have been reached a statistical 
significance after 26 weeks of follow-up (P<0.001). 
4. DISCUSSION 
It is well known that extracellular matrix (ECM) 
proteins may modulate cell–matrix interactions and cell 
function, and they do not seem to have a direct 
structural role and mediate left ventricular remodeling. 
Several members of the matricellular protein family, like 
OSN, are up-regulated in CHF. In fact, OSN (also 
known as Secreted Protein Acidic and Rich in Cysteine 
- SPARC) is synthesized by wide spectrum cells, such 
as osteoblasts, fibroblasts, and activated macrophages 
Table 2: Independent Variables Related to 3-Years All-Cause Mortality, CHF-Related Death, and CHF-Related 
Rehospitalisation, Obtained By Logistic Regression Analysis 
All-Cause Mortality CHF-Related Death CHF-Related Rehospitalisation Variables 
OR 95% CI P OR 95% CI P OR 95% CI P 
OSN 1.23 1.10–1.36 0.006 1.46 1.22–1.80 0.004 1.92 1.77 – 2.45 0.001 
NT-pro-BNP 1.09 1.02–1.16 0.002 1.42 1.22–1.73 0.006 1.44 1.28–1.67 0.002 
LVEF 1.06 1.01–1.12 0.001 1.15 1.12–1.18 0.014 1.22 1.07–1.45 0.016 
T2DM 1.05 1.01–1.11 0.001 1.03 0.93–1.10 0.32 1.04 0.97–1.06 0.42 
Three- and multi-vessel 
lesion of coronary arteries 
1.02 0.88–1.09 0.56 1.01 0.92–1.07 0.27 1.14 1.03–1.26 0.012 
Note: OR – odds ratio, CI – confidence interval; LVEF – left ventricular ejection fraction; BNP – brain natriuretic peptide; T2DM – type two diabetes mellitus. 
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Area Under the Curve 
Asymptotic 95% Confidence Interval 
Test Result Variables Area Std. Error
a
 Asymptotic Sig.
b
 
Lower Bound Upper Bound 
OSN 0.918 0.022 0.001 0.876 0.961 
NT-pro-BNP 0.865 0.029 0.001 0.808 0.922 
OSN + NT-pro-BNP 0.961 0.016 0.001 0.929 0.993 
The test result variables: OSN, NT-pro-BNP, OSN + NT-pro-BNP have at least one tie between the positive actual state group and the negative 
actual state group. Statistics may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
Figure 1: Results of the Receive Operation Characteristic analysis: The graphical plot illustrates the performance of 
discriminations for OSN alone, NT-pro-BNP alone and its combination of both biological markers for cumulative survival in CHF 
patients. 
 
Figure 2: Results of Kaplan-Meier survival analysis: The cumulative survival in two group’s patients with low (<845.15 ng/mL) 
and high (>845.15 ng/mL) circulating OSN. 
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at sites of wound repair and platelet degranulation [3]. 
Elevated OSN was found in the serum of patients with 
CHF and it predominantly reflected a positive pro-
inflammatory response and alterations in protein 
metabolism leaded to biomechanical stress [2-4]. OSN 
may regulate the proliferation of some cells, especially 
endothelial cells; mediate by its ability to bind to 
cytokines and circulating growth factors [5]. As a result 
in excess degradation and disruption of the cardiac 
ECM network structure thereby OSN over expression is 
formation of fibrotic lesions. Because myocardial 
fibrosis is also a well-known cause of diastolic 
dysfunction and CHF, remodeling of ECM is 
considered a key aspect of myocardial response to 
biomechanical stress and advanced heart failure [13]. 
Recent studies have suggested that SPARC proteins, 
such as OSN, osteopontin and osteoprotegrin, are able 
presumably to play an important role in atherogenesis 
too [14, 15]. The animal models give arised evidences 
regarding osteonectin level directly correlates with 
increased mortality in animals with MI [16]. Probably, 
this effect may be related to OSN inhibition ability of 
mitogenesis of vascular endothelial growth factor on 
microvascular endothelial cells [17]. Because OSN may 
induce deadhesion, through loss of actin fibers and 
focal adhesion plaques, cell migration and cell 
infiltration of vulnerable zone of plaque may facilitate. 
Thereby OSN regulates MMP activity involved in 
regulating matrix rearrangement during remodeling of 
the vessels too [17, 18]. Both these processes are 
considered pivotal mechanism for triggering plaque 
instability as well as heart wall rupture [19]. Thus, OSN 
is considered a multifunctional matrix protein with 
powerful ability to inhibition of tissue response to injury, 
and, probably, mediation of low-intensity inflammation. 
In fact, the predictive role of OSN in cardiovascular 
diseases is uncertain. Taken together the all data 
mentioned above clarify that OSN may be considered 
biological marker with high predictive value for CHF 
evolution, especially for patients with ischemic causes 
of myocardial dysfunction. Currently there are not 
consisted data on the utility or discriminatory ability of 
OSN in determining of the mortality related to CHF. It is 
suggested that increased OSN might be powerful 
indicator of CHF-related events and all-cause mortality 
rate. We found that circulating OSN level was 
significantly increased among CHF patients with poor 
short-term prognosis. Indeed, OSN concentration 
independently predicted all-cause mortality, CHF-
related death, and CHF-related readmissions. On the 
one hand, OSN is secreted by activated macrophages 
due to pro-inflammatory activation and leads to 
profound extracellular matrix reposition, exaggerated 
left ventricular remodeling, endothelial dysfunction, 
vascular calcification, and coagulation [1, 3]. On the 
other hand, given results of recent investigations, 
absence of tissue over-expression of OSN associates 
with increased cardiac rupture and dysfunction after 
acute myocardial infarction due to worsening post-
synthetic procollagen processing [20, 21]. There are 
predispositions that these mechanisms, which are 
involved in reparation of heart and vessels, are under 
control of mineralcorticoid receptors. It has been 
postulated that beneficial effect of aldosterone receptor 
antagonist eplerenone in CHF was associated with 
normalization of matricellular protein expression, such 
as OSN [22]. Decreased OSN expression improves 
cardiac structural and functional parameters, delaying 
the progression of heart failure that was found in small 
animal study [22].Thus, role of OSN in cardiac 
outcomes is probably controversial. We have enrolled 
in our study patients with ischemic CHF treated with 
eplerenone too. At least 42.9% and 52.6% patients of 
the both cohorts (died persons and survivors subjects) 
are given mineralcorticoid receptor antagonist 
eplerenone. Despite similar co-administration of 
eplerenone with standard heart failure therapy, no 
significant effect of medication for survival rate of the 
patients with CHF was found. Probably, collagen 
deposition as functions in the extracellular processing 
that is controlled by OSN is a key protective event for 
acute myocardial infarction, whereas for advance CHF 
similar process is considered potential harm and 
prognostically negative [2, 3, 5]. Obviously, structural 
changes of the extracellular matrix are significantly 
modulated by OSN associates several signaling 
pathways, which are differed on their ability to induce 
repair changes on the several stages on cardiovascular 
continuum [23, 24]. It may a have important value for 
risk re-classification of the patients with ischemic CHF. 
We also determined that predictive value of circulating 
OSN was superior when compared with NT-pro-BNP 
alone, while combination of both biological markers 
was able to better prognostic discriminate between 
survived and died patients with ischemic CHF. Taken 
into consideration that a significant divergence of 
Kaplan-Meier survival curves constructed for patients 
with high (> 845.15 ng/mL) and low (<845.15 ng/mL) 
concentrations of OSN was found after 26 weeks of 
follow-up period. The convergence of Kaplan-Meier 
survival curves at the study end was not found. There 
are data about age-related increasing of OSN [15], but 
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we found no substantial age and gender differences of 
OSN among persons who died and survived. Because 
weak association of the echocardiographic score with 
NYHA class was previously determined, we advocate 
screening all CHF patients with circulating OSN added 
to conventional prognostic model tools, such as NT-
pro-BNP and LVEF, and probably to assist with the 
optimum timing of other drugs interventions to be 
improving prognosis. In fact, long term prospective 
studies are required to provide robust evidence of the 
prognostic role of combination OSN and NT-pro-BNP in 
the associated mortality from CHF. However, some 
limitation of our study, such as small size, absence of 
randomization, and, probably, conventional treatment 
of CHF without biological markers-guided control, may 
limit real-time prognostic value of OSN leading 
increased statistical power. In this study, OSN level 
was measured at baseline after discharge of the 
patients from the hospital with stable coronary artery 
disease and without clinical signs and symptoms of 
acute decompensated CHF. It can introduce some 
limitations to the interpretation of the results of the 
investigation, especially around OSN level in CHF 
subjects independently before readmission. New 
studies are required for determination whether OSN 
may predict cardiovascular outcomes in ischemic CHF 
patients. Therefore, understanding the mechanisms 
that contribute to the cardiac remodeling may help to 
design new studies aimed at determination of OSN role 
in CHF. 
CONCLUSION 
We suggest that increased circulating SPARC 
family member OSN closely associates with increased 
three-year CHF-related death, all-cause mortality, and 
risk for readmission due to CHF. 
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